Failure of low-dose recombinant human IL-2 to support the survival of virus-specific CTL clones infused into severe combined immunodeficient foals: Lack of correlation between in vitro activity and in vivo efficacy

Veterinary Immunology and Immunopathology

Volumn 121, Issue 1-2, 2008, Pages 8-22

  Mealey, Robert H ^a   Littke, Matt H ^a   Leib, Steven R ^a   Davis, William C ^a   McGuire, Travis C ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Adoptive transfer; CTL; EIAV; Horse; IL 2; SCID

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR; NEUTRALIZING ANTIBODY; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CELL SURVIVAL; COMBINED IMMUNODEFICIENCY; CYTOTOXIC T LYMPHOCYTE; ENGRAFTMENT; FOAL; LENTIVIRINAE; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; VIRUS LOAD; VIRUS REPLICATION;

ADOPTIVE TRANSFER; ANIMALS; ANIMALS, NEWBORN; BODY TEMPERATURE; CELL SURVIVAL; EQUINE INFECTIOUS ANEMIA; FEMALE; HORSES; IMMUNOTHERAPY; INFECTIOUS ANEMIA VIRUS, EQUINE; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; MALE; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEVERE COMBINED IMMUNODEFICIENCY; T-LYMPHOCYTES, CYTOTOXIC;

EQUIDAE; EQUINE INFECTIOUS ANEMIA VIRUS;

EID: 36849038442     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2007.07.011     Document Type: Article

References (79)

1. Aladdin H., Larsen C.S., Moller B.K., Ullum H., Buhl M.R., Gerstoft J., Skinhoj P., and Pedersen B.K. Effects of subcutaneous interleukin-2 therapy on phenotype and function of peripheral blood mononuclear cells in human immunodeficiency virus infected patients. Scand. J. Immunol. 51 (2000) 168-175
2. Alexander-Miller M.A., Leggatt G.R., and Berzofsky J.A. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 4102-4107
3. Altfeld M., and Rosenberg E.S. The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1. Curr. Opin. Immunol. 12 (2000) 375-380
4. Baigent G. Recombinant Interleukin-2 (rIL-2), aldesleukin. J. Biotechnol. 95 (2002) 277-280
5. Bailey E. Identification and genetics of horse lymphocyte alloantigens. Immunogenetics 11 (1980) 499-506
6. Barouch D.H., Craiu A., Santra S., Egan M.A., Schmitz J.E., Kuroda M.J., Fu T.M., Nam J.H., Wyatt L.S., Lifton M.A., Krivulka G.R., Nickerson C.E., Lord C.I., Moss B., Lewis M.G., Hirsch V.M., Shiver J.W., and Letvin N.L. Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys. J. Virol. 75 (2001) 2462-2467
7. Barouch D.H., Santra S., Kuroda M.J., Schmitz J.E., Plishka R., Buckler-White A., Gaitan A.E., Zin R., Nam J.H., Wyatt L.S., Lifton M.A., Nickerson C.E., Moss B., Montefiori D.C., Hirsch V.M., and Letvin N.L. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J. Virol. 75 (2001) 5151-5158
8. Barouch D.H., Santra S., Schmitz J.E., Kuroda M.J., Fu T.M., Wagner W., Bilska M., Craiu A., Zheng X.X., Krivulka G.R., Beaudry K., Lifton M.A., Nickerson C.E., Trigona W.L., Punt K., Freed D.C., Guan L., Dubey S., Casimiro D., Simon A., Davies M.E., Chastain M., Strom T.B., Gelman R.S., Montefiori D.C., Lewis M.G., Emini E.A., Shiver J.W., and Letvin N.L. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290 (2000) 486-492
9. Belshan M., Baccam P., Oaks J.L., Sponseller B.A., Murphy S.C., Cornette J., and Carpenter S. Genetic and biological variation in equine infectious anemia virus Rev correlates with variable stages of clinical disease in an experimentally infected pony. Virology 279 (2001) 185-200
10. Berger D.P., Homann D., and Oldstone M.B. Defining parameters for successful immunocytotherapy of persistent viral infection. Virology 266 (2000) 257-263
11. Betts M.R., Krowka J.F., Kepler T.B., Davidian M., Christopherson C., Kwok S., Louie L., Eron J., Sheppard H., and Frelinger J.A. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. AIDS Res. Hum. Retroviruses 15 (1999) 1219-1228
12. Blanchard-Channell M., Moore P.F., and Stott J.L. Characterization of monoclonal antibodies specific for equine homologues of CD3 and CD5. Immunology 82 (1994) 548-554
13. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., and Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68 (1994) 6103-6110
14. Brodie S.J., Lewinsohn D.A., Patterson B.K., Jiyamapa D., Krieger J., Corey L., Greenberg P.D., and Riddell S.R. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat. Med. 5 (1999) 34-41
15. Brodie S.J., Patterson B.K., Lewinsohn D.A., Diem K., Spach D., Greenberg P.D., Riddell S.R., and Corey L. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J. Clin. Invest. 105 (2000) 1407-1417
16. Cheng L.E., Ohlen C., Nelson B.H., and Greenberg P.D. Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 3001-3006
17. Chung C., Mealey R.H., and McGuire T.C. Evaluation of high functional avidity CTL to Gag epitope clusters in EIAV carrier horses. Virology 342 (2005) 228-239
18. Crawford T.B., Wardrop K.J., Tornquist S.J., Reilich E., Meyers K.M., and McGuire T.C. A primary production deficit in the thrombocytopenia of equine infectious anemia. J. Virol. 70 (1996) 7842-7850
19. Davey R.T.J., Chaitt D.G., Piscitelli S.C., Wells M., Kovacs J.A., Walker R.E., Falloon J., Polis M.A., Metcalf J.A., Masur H., Fyfe G., and Lane H.C. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J. Infect. Dis. 175 (1997) 781-789
20. Derby M., Alexander-Miller M., Tse R., and Berzofsky J. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J. Immunol. 166 (2001) 1690-1697
21. Doyle M.V., Lee M.T., and Fong S. Comparison of the biological activities of human recombinant interleukin-2(125) and native interleukin-2. J. Biol. Response Mod. 4 (1985) 96-109
22. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., Duray P., Seipp C.A., Rogers-Freezer L., Morton K.E., Mavroukakis S.A., White D.E., and Rosenberg S.A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
23. Flynn J.N., Pistello M., Isola P., Zaccaro L., Del Santo B., Ricci E., Matteucci D., and Bendinelli M. Adoptive immunotherapy of feline immunodeficiency virus with autologous ex vivo-stimulated lymphoid cells modulates virus and T-cell subsets in blood. Clin. Diagn. Lab Immunol. 12 (2005) 736-745
24. Gallimore A., Dumrese T., Hengartner H., Zinkernagel R.M., and Rammensee H.G. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J. Exp. Med. 187 (1998) 1647-1657
25. Gately M.K., Chizzonite R., and Presky D.H. Measurement of human and mouse interleukin-12. Current Protocols in Immunology (1995), John Wiley & Sons, Inc pp. 6.16.1-6.16.15
26. Hammond S.A., Cook S.J., Lichtenstein D.L., Issel C.J., and Montelaro R.C. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J. Virol. 71 (1997) 3840-3852
27. Hines M.T., Palmer G.H., Byrne K.M., Brassfield A.L., and McGuire T.C. Quantitative characterization of lymphocyte populations in bronchoalveolar lavage fluid and peripheral blood of normal adult Arabian horses. Vet. Immunol. Immunopathol. 51 (1996) 29-37
28. Ho M., Armstrong J., McMahon D., Pazin G., Huang X.L., Rinaldo C., Whiteside T., Tripoli C., Levine G., Moody D., et al. A phase 1 study of adoptive transfer of autologous CD8+ T lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS. Blood 81 (1993) 2093-2101
29. Hodgson D.R., McCutcheon L.J., Byrd S.K., Brown W.S., Bayly W.M., Brengelmann G.L., and Gollnick P.D. Dissipation of metabolic heat in the horse during exercise. J. Appl. Physiol. 74 (1993) 1161-1170
30. Hunziker L., Klenerman P., Zinkernagel R.M., and Ehl S. Exhaustion of cytotoxic T cells during adoptive immunotherapy of virus carrier mice can be prevented by B cells or CD4+ T cells. Eur. J. Immunol. 32 (2002) 374-382
31. Jacobson E.L., Pilaro F., and Smith K.A. Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 10405-10410
32. Jin X., Bauer D.E., Tuttleton S.E., Lewin S., Gettie A., Blanchard J., Irwin C.E., Safrit J.T., Mittler J., Weinberger L., Kostrikis L.G., Zhang L., Perelson A.S., and Ho D.D. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189 (1999) 991-998
33. Klein M.R., Van Baalen C.A., Holwerda A.M., Kerkhof Garde S.R., Bende R.J., Keet I.P., Eeftinck Schattenkerk J.K., Osterhaus A.D., Schuitemaker H., and Miedema F. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181 (1995) 1365-1372
34. Klimas N., Patarca R., Walling J., Garcia R., Mayer V., Moody D., Okarma T., and Fletcher M.A. Clinical and immunological changes in AIDS patients following adoptive therapy with activated autologous CD8 T cells and interleukin-2 infusion. AIDS 8 (1994) 1073-1081
35. Koenig S., Conley A.J., Brewah Y.A., Jones G.M., Leath S., Boots L.J., Davey V., Pantaleo G., Demarest J.F., Carter C., et al. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat. Med. 1 (1995) 330-336
36. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., Farthing C., and Ho D.D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68 (1994) 4650-4655
37. Kuroda M.J., Schmitz J.E., Charini W.A., Nickerson C.E., Lifton M.A., Lord C.I., Forman M.A., and Letvin N.L. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J. Immunol. 162 (1999) 5127-5133
38. Lanzavecchia A., and Sallusto F. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science 290 (2000) 92-97
39. Leroux C., Issel C.J., and Montelaro R.C. Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony. J. Virol. 71 (1997) 9627-9639
40. Lonning S.M., Zhang W., Leib S.R., and McGuire T.C. Detection and induction of equine infectious anemia virus-specific cytotoxic T-lymphocyte responses by use of recombinant retroviral vectors. J. Virol. 73 (1999) 2762-2769
41. Lunn D.P., Holmes M.A., Antczak D.F., Agerwal N., Baker J., Bendali-Ahcene S., Blanchard-Channell M., Byrne K.M., Cannizzo K., Davis W., Hamilton M.J., Hannant D., Kondo T., Kydd J.H., Monier M.C., Moore P.F., O'Neil T., Schram B.R., Sheoran A., Stott J.L., Sugiura T., and Vagnoni K.E. Report of the Second Equine Leucocyte Antigen Workshop, Squaw valley, California, July 1995. Vet. Immunol. Immunopathol. 62 (1998) 101-143
42. Lunn D.P., McClure J.T., Schobert C.S., and Holmes M.A. Abnormal patterns of equine leucocyte differentiation antigen expression in severe combined immunodeficiency foals suggests the phenotype of normal equine natural killer cells. Immunology 84 (1995) 495-499
43. Magnuson N.S., Perryman L.E., Wyatt C.R., Ishizaka T., Mason P.H., Namen A.E., Banks K.L., and Magnuson J.A. Continuous cultivation of equine lymphocytes: evidence for occasional T cell-like maturation events in horses with hereditary severe combined immunodeficiency. J. Immunol. 133 (1984) 2518-2524
44. Magnuson N.S., Perryman L.E., Wyatt C.R., Mason P.H., and Talmadge J.E. Large granular lymphocytes from SCID horses develop potent cytotoxic activity after treatment with human recombinant interleukin 2. J. Immunol. 139 (1987) 61-67
45. McGuire T.C., Leib S.R., Lonning S.M., Zhang W., Byrne K.M., and Mealey R.H. Equine infectious anaemia virus proteins with epitopes most frequently recognized by cytotoxic T lymphocytes from infected horses. J. Gen. Virol. 81 (2000) 2735-2739
46. McGuire T.C., Leib S.R., Mealey R.H., Fraser D.G., and Prieur D.J. Presentation and binding affinity of equine infectious anemia virus CTL envelope and matrix protein epitopes by an expressed equine classical MHC class I molecule. J. Immunol. 171 (2003) 1984-1993
47. McGuire T.C., Poppie M.J., and Banks K.L. Combined (B- and T-lymphocyte) immunodeficiency: a fatal genetic disease in Arabian foals. J. Am. Vet. Med. Assoc. 164 (1974) 70-76
48. McGuire T.C., Tumas D.B., Byrne K.M., Hines M.T., Leib S.R., Brassfield A.L., O'Rourke K.I., and Perryman L.E. Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins. J. Virol. 68 (1994) 1459-1467
49. Mealey R.H., Fraser D.G., Oaks J.L., Cantor G.H., and McGuire T.C. Immune reconstitution prevents continuous equine infectious anemia virus replication in an Arabian foal with severe combined immunodeficiency: lessons for control of lentiviruses. Clin. Immunol. 101 (2001) 237-247
50. Mealey R.H., Lee J.H., Leib S.R., Littke M.H., and McGuire T.C. A single amino acid difference within the alpha-2 domain of two naturally occurring equine MHC class I molecules alters the recognition of Gag and Rev epitopes by equine infectious anemia virus-specific CTL. J. Immunol. 177 (2006) 7377-7390
51. Mealey R.H., Leib S.R., Pownder S.L., and McGuire T.C. Adaptive immunity is the primary force driving selection of equine infectious anemia virus envelope SU variants during acute infection. J. Virol. 78 (2004) 9295-9305
52. Mealey R.H., et al. Cloning and large-scale expansion of epitope-specific cytotoxic T lymphocytes using an anti-equine CD3 monoclonal antibody and human recombinant IL-2. Vet. Immunol. Immunopathol. 118 (2007) 121-128
53. Mealey R.H., Sharif A., Ellis S.A., Littke M.H., Leib S.R., and McGuire T.C. Early detection of dominant Env-specific and subdominant Gag-specific CD8+ lymphocytes in equine infectious anemia virus-infected horses using major histocompatibility complex class I/peptide tetrameric complexes. Virology 339 (2005) 110-126
54. Mealey R.H., Zhang B., Leib S.R., Littke M.H., and McGuire T.C. Epitope specificity is critical for high and moderate avidity cytotoxic T lymphocytes associated with control of viral load and clinical disease in horses with equine infectious anemia virus. Virology 313 (2003) 537-552
55. Mitsuyasu R.T., Anton P.A., Deeks S.G., Scadden D.T., Connick E., Downs M.T., Bakker A., Roberts M.R., June C.H., Jalali S., Lin A.A., Pennathur-Das R., and Hege K.M. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 96 (2000) 785-793
56. Ogg G.S., Jin X., Bonhoeffer S., Dunbar P.R., Nowak M.A., Monard S., Segal J.P., Cao Y., Rowland-Jones S.L., Cerundolo V., Hurley A., Markowitz M., Ho D.D., Nixon D.F., and McMichael A.J. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279 (1998) 2103-2106
57. O'Rourke K.I., Perryman L.E., and McGuire T.C. Cross-neutralizing and subclass characteristics of antibody from horses with equine infectious anemia virus. Vet. Immunol. Immunopathol. 23 (1989) 41-49
58. Perryman L.E., McGuire T.C., and Crawford T.B. Maintenance of foals with combined immunodeficiency: causes and control of secondary infections. Am. J. Vet. Res. 39 (1978) 1043-1047
59. Perryman L.E., O'Rourke K.I., and McGuire T.C. Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection. J. Virol. 62 (1988) 3073-3076
60. Perryman L.E., and Torbeck R.L. Combined immunodeficiency of Arabian horses: confirmation of autosomal recessive mode of inheritance. J. Am. Vet. Med. Assoc. 176 (1980) 1250-1251
61. Pu R., Omori M., Okada S., Rine S.L., Lewis B.A., Lipton E., and Yamamoto J.K. MHC-restricted protection of cats against FIV infection by adoptive transfer of immune cells from FIV-vaccinated donors. Cell Immunol. 198 (1999) 30-43
62. Rinaldo C., Huang X.L., Fan Z.F., Ding M., Beltz L., Logar A., Panicali D., Mazzara G., Liebmann J., Cottrill M., et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 69 (1995) 5838-5842
63. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., Racz P., Tenner-Racz K., Dalesandro M., Scallon B.J., Ghrayeb J., Forman M.A., Montefiori D.C., Rieber E.P., Letvin N.L., and Reimann K.A. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283 (1999) 857-860
64. Shin E.K., Perryman L.E., and Meek K. A kinase-negative mutation of DNA-PK(CS) in equine SCID results in defective coding and signal joint formation. J. Immunol. 158 (1997) 3565-3569
65. Siliciano R.F., Keegan A.D., Dintzis R.Z., Dintzis H.M., and Shin H.S. The interaction of nominal antigen with T cell antigen receptors. I. Specific binding of multivalent nominal antigen to cytolytic T cell clones. J. Immunol. 135 (1985) 906-914
66. Smith K.A. The interleukin 2 receptor. Annu. Rev. Cell Biol. 5 (1989) 397-425
67. Sundin D.J., and Wolin M.J. Aldesleukin therapy in HIV-infected patients. Am. J. Health Syst. Pharm. 55 (1998) 1520-1523
68. Tan R., Xu X., Ogg G.S., Hansasuta P., Dong T., Rostron T., Luzzi G., Conlon C.P., Screaton G.R., McMichael A.J., and Rowland-Jones S. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Blood 93 (1999) 1506-1510
69. Terasaki P.I., Bernoco D., Park M.S., Ozturk G., and Iwaki Y. Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture. Am. J. Clin. Pathol. 69 (1978) 103-120
70. Tschetter J.R., Davis W.C., Perryman L.E., and McGuire T.C. CD8 dimer usage on alpha beta and gamma delta T lymphocytes from equine lymphoid tissues. Immunobiology 198 (1998) 424-438
71. Tsoukas C.M., Turner H.M., Hatzakis G.E., Blake G.P., Goodhew J.E., Kilby D.L., Kovacs C.M., Luetkehoelter J.R., Routy J.P., Walmsley S.L., and Bernard N.F. Improvement of HIV-specific immunity in HIV-infected twins treated with highly active antiretroviral therapy, interleukin 2, and syngeneic adoptively transferred cells. AIDS Res. Hum. Retroviruses 17 (2001) 887-900
72. Villinger F., Brice G.T., Mayne A.E., Bostik P., Mori K., June C.H., and Ansari A.A. Adoptive transfer of simian immunodeficiency virus (SIV) naive autologous CD4(+) cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status. Blood 99 (2002) 590-599
73. Walker R.E., Bechtel C.M., Natarajan V., Baseler M., Hege K.M., Metcalf J.A., Stevens R., Hazen A., Blaese R.M., Chen C.C., Leitman S.F., Palensky J., Wittes J., Davey Jr. R.T., Falloon J., Polis M.A., Kovacs J.A., Broad D.F., Levine B.L., Roberts M.R., Masur H., and Lane H.C. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 96 (2000) 467-474
74. Wang A., Lu S.D., and Mark D.F. Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues. Science 224 (1984) 1431-1433
75. Wiler R., Leber R., Moore B.B., VanDyk L.F., Perryman L.E., and Meek K. Equine severe combined immunodeficiency: a defect in V(D)J recombination and DNA-dependent protein kinase activity. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 11485-11489
76. Wilson J.D., Ogg G.S., Allen R.L., Davis C., Shaunak S., Downie J., Dyer W., Workman C., Sullivan S., McMichael A.J., and Rowland-Jones S.L. Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. AIDS 14 (2000) 225-233
77. Wyatt C.R., Magnuson N.S., and Perryman L.E. Defective thymocyte maturation in horses with severe combined immunodeficiency. J. Immunol. 139 (1987) 4072-4076
78. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., and Greenberg P.D. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 16168-16173
79. Zhang W., Lonning S.M., and McGuire T.C. Gag protein epitopes recognized by ELA-A-restricted cytotoxic T lymphocytes from horses with long-term equine infectious anemia virus infection. J. Virol. 72 (1998) 9612-9620